Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRTSNASDAQ:MDAINYSE:NVRONASDAQ:SGHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRTSAlpha Tau Medical$3.07$2.78$1.75▼$4.39$216.07M0.9950,290 shs16,959 shsMDAISpectral AI$2.13+3.9%$1.40$0.82▼$3.25$53.93M0.7855,400 shs211,725 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.37$224.32M0.81785,415 shs753,602 shsSGHTSight Sciences$4.21+0.5%$3.16$2.03▼$8.45$217.64M2.46215,983 shs79,296 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRTSAlpha Tau Medical-0.65%+4.42%+9.64%+17.18%+33.48%MDAISpectral AI-2.84%+19.19%+50.74%+48.55%+19.88%NVRONevro0.00%0.00%0.00%+0.71%-36.80%SGHTSight Sciences+0.48%-1.18%+30.53%+74.58%-37.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRTSAlpha Tau Medical2.9317 of 5 stars3.55.00.00.02.71.70.0MDAISpectral AI3.6273 of 5 stars3.75.00.00.03.33.30.0NVRONevro0.16 of 5 stars1.00.00.00.00.01.70.6SGHTSight Sciences1.6264 of 5 stars1.14.00.00.02.44.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRTSAlpha Tau Medical 3.00Buy$8.00160.59% UpsideMDAISpectral AI 3.33Buy$4.75123.00% UpsideNVRONevro 1.92Reduce$5.36-8.29% DownsideSGHTSight Sciences 2.29Hold$4.02-4.59% DownsideCurrent Analyst Ratings BreakdownLatest MDAI, NVRO, SGHT, and DRTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.20 ➝ $3.605/9/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$2.50 ➝ $3.004/29/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/9/2025SGHTSight SciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/2/2025MDAISpectral AIHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.503/18/2025MDAISpectral AIHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.503/17/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRTSAlpha Tau MedicalN/AN/AN/AN/A$1.21 per shareN/AMDAISpectral AI$29.96M1.80N/AN/A($0.10) per share-21.30NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72SGHTSight Sciences$78.11M2.79N/AN/A$2.47 per share1.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRTSAlpha Tau Medical-$29.16M-$0.46N/AN/AN/AN/A-38.62%-29.89%8/13/2025 (Estimated)MDAISpectral AI-$20.85M-$0.54N/AN/AN/A-40.78%N/A-77.87%N/ANVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)SGHTSight Sciences-$55.55M-$0.98N/AN/AN/A-63.30%-47.28%-32.72%7/30/2025 (Estimated)Latest MDAI, NVRO, SGHT, and DRTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025DRTSAlpha Tau Medical-$0.14-$0.12+$0.02-$0.12$0.03 millionN/A5/8/2025Q1 2025SGHTSight Sciences-$0.29-$0.28+$0.01-$0.28$16.51 million$17.51 million3/27/2025Q4 2024MDAISpectral AI-$0.13-$0.06+$0.07-$0.41$6.83 million$7.60 million3/12/2025Q4 2024DRTSAlpha Tau Medical-$0.13-$0.13N/A-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRTSAlpha Tau MedicalN/AN/AN/AN/AN/AMDAISpectral AIN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRTSAlpha Tau Medical0.0810.99N/AMDAISpectral AIN/A0.730.69NVRONevro0.675.023.76SGHTSight Sciences0.3610.189.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRTSAlpha Tau Medical2.65%MDAISpectral AI67.08%NVRONevro95.52%SGHTSight Sciences55.51%Insider OwnershipCompanyInsider OwnershipDRTSAlpha Tau Medical39.50%MDAISpectral AI30.70%NVRONevro3.20%SGHTSight Sciences30.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRTSAlpha Tau Medical8070.38 million42.30 millionNo DataMDAISpectral AI8325.32 million8.04 millionNot OptionableNVRONevro1,09038.37 million36.27 millionOptionableSGHTSight Sciences21051.70 million36.09 millionOptionableMDAI, NVRO, SGHT, and DRTS HeadlinesRecent News About These CompaniesMillennium Management LLC Invests $464,000 in Sight Sciences, Inc. (NASDAQ:SGHT)June 10 at 3:12 AM | marketbeat.comsight sciences appoints new board member and holds annual meetingJune 7, 2025 | uk.investing.comSquarepoint Ops LLC Buys 128,355 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)June 4, 2025 | marketbeat.comBrokerages Set Sight Sciences, Inc. (NASDAQ:SGHT) Price Target at $4.02June 2, 2025 | americanbankingnews.comSight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Rating of "Hold" from AnalystsMay 31, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Shares Sold by Bank of America Corp DEMay 30, 2025 | marketbeat.comBNP Paribas Financial Markets Invests $262,000 in Sight Sciences, Inc. (NASDAQ:SGHT)May 30, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Acquires 88,738 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)May 25, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Sells 135,268 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)May 21, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Shares Purchased by Dimensional Fund Advisors LPMay 18, 2025 | marketbeat.comProsight Management LP Acquires 377,625 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)May 17, 2025 | marketbeat.comSight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27thMay 14, 2025 | globenewswire.comBrokers Set Expectations for Sight Sciences Q1 EarningsMay 13, 2025 | marketbeat.comSight Sciences stock holds as Needham reiterates ratingMay 11, 2025 | uk.investing.comSight Sciences, Inc. (SGHT) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comSight Sciences, Inc. (NASDAQ:SGHT) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comSight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue GuidanceMay 10, 2025 | finance.yahoo.comSight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 8, 2025 | zacks.comSight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comWhy Sight Sciences, Inc.’s (SGHT) Stock Is Down 5.02%April 26, 2025 | aaii.comSight Sciences appoints new board memberApril 24, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDAI, NVRO, SGHT, and DRTS Company DescriptionsAlpha Tau Medical NASDAQ:DRTS$3.07 0.00 (0.00%) As of 03:58 PM EasternAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Spectral AI NASDAQ:MDAI$2.13 +0.08 (+3.90%) As of 04:00 PM EasternSpectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.Nevro NYSE:NVRO$5.85 +0.01 (+0.10%) Closing price 04/2/2025Extended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Sight Sciences NASDAQ:SGHT$4.21 +0.02 (+0.48%) As of 04:00 PM EasternSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
